

**MD MEDICAL GROUP REPORTS GROWTH ACROSS ALL  
OPERATIONAL INDICATORS FOR Q1 2017**

**20 April 2017**, Moscow – MD Medical Group Investments Plc (“MD Medical Group”, “MDMG” or the “Company” – LSE: MDMG), a leading Russian private healthcare provider, today announces its operating results for the first quarter of 2017.

**Key operational highlights for Q1 2017:**

- Total IVF cycles increased 19% year-on-year (y-o-y) to 3,359
- Total deliveries increased 3% y-o-y to 1,603
- Total in-patient treatments increased 8% y-o-y to 14,650
- Total out-patient treatments increased 9% y-o-y to 364,016

**Mark Kurtser, CEO of MD Medical Group, said:**

*“In the first quarter of 2017, MD Medical Group demonstrated strong operational performance.*

*“We are the leader in the IVF market in Russia, and our results in this segment grew by an impressive 19% year-on-year, further strengthening our leadership. In-patient and out-patient treatments grew 8% and 9% year-on-year, respectively. Over the first three months of the year, we had 3% more deliveries than in Q1 2016.*

*“This growth was mainly driven by the continued ramp-up of our hospitals in Ufa, Novosibirsk, and Lapino, as well as the further development of other medical facilities across Russia.*

*“In Q1 2017, we further expanded our leading network in the regions. In February, we completed one of our largest projects to date – in line with the timeframe and budget, we built a new high-tech hospital in Novosibirsk, which is becoming a powerful healthcare hub in Siberia. In March, we welcomed the first patients at the hospital. We significantly expanded and modernised our clinic in St Petersburg, growing the range of the services offered and increasing capacity. We also opened our first IVF clinic in Vladimir.*

*“The Group continues to grow. The demand for our high-tech health care services remains strong, as ever. Thanks to our recent launches, continued ramp-up at our existing facilities and the pipeline of upcoming projects, we are optimistic about the future.”*

- In Q1 2017, total IVF cycles rose 19% y-o-y to 3,359.
- LFL<sup>1</sup> 3,245 IVF cycles were performed in Q1 2017, up 15% y-o-y.

### **Deliveries**

- In Q1 2017, total deliveries increased 3% y-o-y to 1,603.
- There were 263 deliveries at Mother & Child Ufa hospital in Q1 2017.

### **In-patient treatments**

- In Q1 2017, total in-patient treatments grew 8% y-o-y to 14,650, driven by:
  - 3% increase in paediatric in-patient treatments;
  - 37% increase in in-patient days using other medical services.
- LFL in-patient treatments increased 7% y-o-y in Q1 2017 to 14,487.

### **Out-patient treatments**

- In Q1 2017, the total number of out-patient treatments increased 9% y-o-y to 364,016, driven by:
  - 6% increase in OBGYN out-patient treatments;
  - 11% rise in paediatric out-patient visits;
  - 11% increase in other medical services.
- LFL out-patient treatments increased 9% y-o-y in Q1 2017 to 359,089.

---

<sup>1</sup> LFL data does not include figures for the Mother and Child Khodynskoe Pole clinic in Moscow, which opened in June 2016.

TOTAL				LFL		
	Q1 2017	Q1 2016	y-o-y, %	Q1 2017	Q1 2016	y-o-y, %
<b>Obstetrics and Gynaecology</b>						
Deliveries	1,603	1,561	3%	1,603	1,561	3%
In-patient treatments (except deliveries)	5,997	6,000	0%	5,997	6,000	0%
Out-patient treatments	127,954	121,127	6%	123,027	118,197	4%
<b>IVF</b>						
	3,359	2,812	19%	3,245	2,812	15%
<b>Paediatrics</b>						
In-patient treatments	4,956	4,804	3%	4,956	4,804	3%
Out-patient treatments	102,694	92,309	11%	102,694	92,309	11%
<b>Other medical services</b>						
In-patient treatments	3,697	2,700	37%	3,534	2,700	31%
Out-patient treatments	133,368	119,619	11%	133,368	119,619	11%
<b>Total</b>						
<b>Total deliveries</b>	<b>1,603</b>	<b>1,561</b>	<b>3%</b>	<b>1,603</b>	<b>1,561</b>	<b>3%</b>
<b>Total IVF</b>	<b>3,359</b>	<b>2,812</b>	<b>19%</b>	<b>3,245</b>	<b>2,812</b>	<b>15%</b>
<b>Total in-patient treatments</b>	<b>14,650</b>	<b>13,504</b>	<b>8%</b>	<b>14,487</b>	<b>13,504</b>	<b>7%</b>
<b>Total out-patient treatments</b>	<b>364,016</b>	<b>333,055</b>	<b>9%</b>	<b>359,089</b>	<b>330,125</b>	<b>9%</b>

**This announcement contains inside information.**

**For further information please contact:**

**Investors**

Elena Romanova  
MD Medical Group Investments Plc

Tel: +7 495 331 4120  
[e.romanova@mcclinics.ru](mailto:e.romanova@mcclinics.ru)

**Media**

**EM**

Tom Blackwell: +7 919 102 9064

Sergii Pershyn: +1 929 855 8188

[MDMG@em-comms.com](mailto:MDMG@em-comms.com)

**About MD Medical Group**

MD Medical Group operates in the highly attractive Russian private healthcare service market and has a leading position in high-quality women's health and paediatrics. The company manages 32 modern healthcare facilities, including 4 hospitals and 28 outpatient clinics in Moscow and Moscow region, St. Petersburg, Ufa, Perm, Samara and Samara region, Irkutsk, Novosibirsk, Irkutsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, Barnaul, and Vladimir.

The Company's shares have been listed on the London Stock Exchange (LSE ticker "MDMG") in the form of Global Depositary Receipts (GDRs) since 12 October 2012.

**Forward-Looking Statements:**

This press release contains forward looking statements, which are based on the Company's current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company's ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.

No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.

